BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TagEnergy Selects Sitetracker to Accelerate Renewable Energy Growth20.10.2025 15:00:00 CEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that TagEnergy, a fast-growing renewable energy producer, has selected Sitetracker to standardize operations and scale its portfolio across multiple markets. The move underscores TagEnergy’s commitment to delivering clean energy projects more efficiently while maintaining the highest standards of quality and transparency. TagEnergy develops and operates wind, solar, and battery storage projects across Europe, Japan and Australia, and is on track to double its size in the next three to four years. To support this growth, the company required a modern, flexible platform to unify processes across departments and countries, eliminate reliance on spreadsheets, and provide real-time visibility into project performance. By deploying Sitetracker, TagEnergy will: Get more done faster by eliminating manual tasks, standardizing workflows, and enabling teams to manage more projects wi
Lenovo Advances the AI-Enabled Workforce with Agentic AI: Trusted, Proven, and Ready to Deliver ROI20.10.2025 15:00:00 CEST | Press release
IDC projects agentic AI to double workforce productivity by 2027, while generative AI is already delivering $4 in return for every $1 invested.Lenovo integrates new agentic AI capabilities across AI PCs, Services, and TruScale DaaS to boost productivity, protection, and enterprise efficiency. As enterprises race to capture value from AI, Lenovo today unveiled new agentic AI capabilities as the centerpiece of its AI-Enabled Workforce portfolio, a complete suite of devices, services, and lifecycle solutions that turn AI investments into measurable business value. According to IDC, enterprises are already realizing nearly $4 in return for every $1 invested in generative AI, and by 2027 agentic AI is expected to double workforce productivity worldwide1 – evidence that organizations are moving from AI experimentation to tangible results. This marks a turning point where enterprises are shifting from piloting AI to embedding intelligent automation across their workforces, and Lenovo is helpi
Global Study: 73% of Shoppers Using AI in Shopping Journey - But Merchants Face New Agentic Commerce Risks20.10.2025 14:00:00 CEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, today released findings from a survey highlighting the increased adoption of agentic shopping, and the rising threat it poses to merchants. Based on a global survey of more than 5,000 consumers, the research reveals a defining moment for ecommerce: nearly three in four shoppers (73%) are already using AI in their shopping journey. Shoppers are embracing AI assistants like ChatGPT for product ideas (45%), to summarize reviews (37%), and to compare prices (32%). While only 13% say they’ve completed a purchase after being referred by an AI assistant, 70% are at least somewhat comfortable with an AI agent making purchases on their behalf. More than half (58%) are likely to use these tools for gift shopping this year, marking the beginning of the first truly AI-powered holiday season, where convenience for consumers may come with heightened exposure for merchants who may bear the liability for this
AI-Driven Cyber Threats Are the Biggest Concern for Cybersecurity Professionals Going Into 2026, Finds New ISACA Research20.10.2025 13:58:00 CEST | Press release
Over half (51%) of European IT and cybersecurity professionals fear AI-driven cyber threats and deepfakes will keep them up at night next year, according to new ISACA research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020612551/en/ What’s driving this concern is a lack of preparedness for AI-related risks across the industry. Only 14% of respondents feel their organisation is very prepared to manage the risks associated with generative AI solutions in 2026. The majority (82%) feel they are only somewhat prepared, not very prepared, or not prepared at all. Tech professionals clearly perceive AI-driven threats as the most concerning, yet other threats persist which pose risks to business continuity. Other than AI-driven threats, regulatory complexity and compliance risks (38%), supply chain vulnerabilities (37%), and the failure to detect and respond to a breach, causing irreparable harm to the business (35%) were als
IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 13:05:00 CEST | Press release
Q-Alliance launch marks a key milestone in Italy’s digital transformation and the country’s ambitious quantum ecosystem goals IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom